Todd C. Skaar

13.0k total citations · 2 hit papers
214 papers, 8.4k citations indexed

About

Todd C. Skaar is a scholar working on Genetics, Pharmacology and Oncology. According to data from OpenAlex, Todd C. Skaar has authored 214 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Genetics, 65 papers in Pharmacology and 64 papers in Oncology. Recurrent topics in Todd C. Skaar's work include Estrogen and related hormone effects (69 papers), Pharmacogenetics and Drug Metabolism (62 papers) and Cancer Treatment and Pharmacology (17 papers). Todd C. Skaar is often cited by papers focused on Estrogen and related hormone effects (69 papers), Pharmacogenetics and Drug Metabolism (62 papers) and Cancer Treatment and Pharmacology (17 papers). Todd C. Skaar collaborates with scholars based in United States, Canada and China. Todd C. Skaar's co-authors include David A. Flockhart, Robert Clarke, Zeruesenay Desta, James M. Rae, Anne Nguyen, Andrea Gaedigk, Fabio Leonessa, Teri E. Klein, Daniel F. Hayes and Vered Stearns and has published in prestigious journals such as Circulation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Todd C. Skaar

207 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

2005 681 citations Zeruesenay Desta, Vered Stearns et al. profile →
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

2014 453 citations Andrea Gaedigk, Henry M. Dunnenberger et al. Clinical Pharmacology & Therapeutics profile →

Peers

Todd C. Skaar

GENET

PHARM

ONCOL

Zeruesenay Desta United States

David A. Flockhart United States

Michelle Whirl‐Carrillo United States

Chantal Guillemette Canada

Jürgen Brockmöller Germany

Miki Nakajima Japan

Stuart A. Scott United States

Ingolf Cascorbi Germany

Andrea Gaedigk United States

Ron H. N. van Schaik Netherlands

Zeruesenay Desta United States

Todd C. Skaar

2.5k ×0.8

GENET

4.0k ×1.3

PHARM

2.4k ×1.0

ONCOL

1.5k ×0.6

753 ×0.7

Citations per year, relative to Todd C. Skaar Todd C. Skaar (= 1×) peers Zeruesenay Desta

Countries citing papers authored by Todd C. Skaar

Since Specialization

Citations

This map shows the geographic impact of Todd C. Skaar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd C. Skaar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd C. Skaar more than expected).

Fields of papers citing papers by Todd C. Skaar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd C. Skaar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd C. Skaar. The network helps show where Todd C. Skaar may publish in the future.

Co-authorship network of co-authors of Todd C. Skaar

This figure shows the co-authorship network connecting the top 25 collaborators of Todd C. Skaar. A scholar is included among the top collaborators of Todd C. Skaar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd C. Skaar. Todd C. Skaar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Skaar, Todd C., et al.. (2025). Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precision Oncology. 9(9). e2500153–e2500153.

Stearns, Vered, Opeyemi A. Jegede, Victor T. Chang, et al.. (2024). A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11. Clinical Cancer Research. 30(13). 2709–2718. 4 indexed citations

Liang, Tiebing, Joseph Ipe, Sha Cao, et al.. (2023). Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nature Communications. 14(1). 1474–1474. 23 indexed citations

Shen, Fei, Guanglong Jiang, Santosh Philips, et al.. (2023). Cytochrome P450 Oxidoreductase ( POR ) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103. Clinical Cancer Research. 29(13). 2494–2500. 2 indexed citations

Ly, Reynold C., Santosh Philips, Milan Radovich, et al.. (2022). Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. JCO Precision Oncology. 6(6). e2100312–e2100312. 11 indexed citations

Ipe, Joseph, et al.. (2022). MicroRNA sequencing in patients with coronary artery disease – considerations for use as biomarker for thrombotic risk. Clinical and Translational Science. 15(8). 1946–1958. 5 indexed citations

Eadon, Michael T., Judith Maddatu, Sharon M. Moe, et al.. (2021). Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360. 3(2). 307–316. 13 indexed citations

Collins, Kimberly S., Arjun Sinha, Asif Sharfuddin, et al.. (2020). Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance. PMC. 1 indexed citations

Lin, Hai, Jill L. Reiter, Yue Wang, et al.. (2019). RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants. Genome biology. 20(1). 254–254. 41 indexed citations

10.

Shao, Minghai, et al.. (2019). MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation. PMC. 1 indexed citations

11.

Gufford, Brandon T., Jason Robarge, Michael T. Eadon, et al.. (2018). Rifampin modulation of xeno‐ and endobiotic conjugating enzymemRNAexpression and associated microRNAs in human hepatocytes. Pharmacology Research & Perspectives. 6(2). e00386–e00386. 22 indexed citations

12.

Gufford, Brandon T., Jason Robarge, Michael T. Eadon, et al.. (2018). Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. PMC. 3 indexed citations

13.

Hicks, J. Kevin, Katrin Sangkuhl, Jesse J. Swen, et al.. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Data Archiving and Networked Services (DANS). 57 indexed citations

14.

Robarge, Jason, Ingrid F. Metzger, Jessica Bo Li Lu, et al.. (2016). Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. PMC. 1 indexed citations

15.

Santa‐Maria, Cesar A., Amanda L. Blackford, Anne Nguyen, et al.. (2015). Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clinical Cancer Research. 22(6). 1395–1402. 18 indexed citations

16.

Guthrie, Katherine A., Andrea Z. LaCroix, Kristine E. Ensrud, et al.. (2015). Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstetrics and Gynecology. 126(2). 413–422. 39 indexed citations

17.

Bishop, Jeffrey R., Katrin Sangkuhl, Daniel J. Müller, et al.. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. PMC. 51 indexed citations

18.

Jiang, Guanglong, Arindom Chakraborty, Zhiping Wang, et al.. (2013). New aQTL SNPs for the CYP2D6 Identified by a Novel Mediation Analysis of Genome-Wide SNP Arrays, Gene Expression Arrays, and CYP2D6 Activity. BioMed Research International. 2013. 1–7. 8 indexed citations

19.

Nguyen, Anne, Vered Stearns, Anne F. Schott, et al.. (2007). Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clinical Pharmacology & Therapeutics. 83(5). 702–710. 31 indexed citations

20.

Ward, Bryan A., Zeruesenay Desta, Tonya J. Roberts, et al.. (2005). Diindolylmethane inhibits indoleamine 2,3-dioxygenase activity in breast cancer cells. Cancer Research. 65. 577–577. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact